Sorafenib in liver cancer

Bibliography

• Lodato F, Mazzella G, Festi D, Hepatocellular carcinoma prevention: a worldwide emergence between the opulence of developed countries and the economic constraints of developing nations. World J Gastroenterol 2006;12:7239-49
   PubMed Web of Science ®Google Scholar
• World Health Organization. Causes of Death 2008: Data Sources and Methods. World Health Organization; Geneva: 2010
   Google Scholar
• Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006;24:2137-50
   PubMed Web of Science ®Google Scholar
• El Serag HB. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2001;5:87-107
   PubMedGoogle Scholar
• Goodgame B, Shaheen NJ, Galanko J, The risk of end stage liver disease and hepatocellular carcinoma among persons infected with hepatitis C virus: publication bias? Am J Gastroenterol 2003;98:2535-42
   PubMedGoogle Scholar
• Deuffic S, Poynard T, Buffat L, Trends in primary liver cancer. Lancet 1998;351:214-15
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E, Cancer statistics. CA Cancer J Clin 2008;58:71-96
   PubMed Web of Science ®Google Scholar
• Ferlay J, Autier P, Boniol M, Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007;18:581-92
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-2
   PubMed Web of Science ®Google Scholar
• Simonetti RG, Camm C, Fiorello F, Hepatocellular carcinoma. A worldwide problem and the major risk factors. Dig Dis Sci 1991;36:962-72
   PubMed Web of Science ®Google Scholar
• Bosch FX, Ribes J, Borrs J. Epidemiology of primary liver cancer. Semin Liver Dis 1999;19:271-85
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-36
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90
   PubMed Web of Science ®Google Scholar
• Cheng A, Kang Y, Chen Z, Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Carter C, Tang L, BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109
   PubMed Web of Science ®Google Scholar
• Hwang YH, Choi JY, Kim S, Over-expression of c-raf-1 proto-oncogene in liver cirrhosis and hepatocellular carcinoma. Hepatol Res 2004;29:113-21
   PubMed Web of Science ®Google Scholar
• Liu L, Cao Y, Chen C, Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006;66:11851-8
   PubMed Web of Science ®Google Scholar
• Furuse J, Ishii H, Nakachi K, Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci 2008;99:159-65
   PubMed Web of Science ®Google Scholar
• Lettieri J, Mazzu A, Huang L, Lathia C. Effect of Hepatic Impairment on sorafenib pharmacokinetics: results of a multicenter, open-label, single-dose, phase I trial. J Clin Oncol 2011;29:abstract 2580
   Google Scholar
• Miller AA, Owzar K, Hollis DR, Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol 2009;27:1800-5
   PubMed Web of Science ®Google Scholar
• Abou Alfa GK, Schwartz L, Ricci S, Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24:4293-300
   PubMedGoogle Scholar
• Bruix J, Cheng A, Kang YK. Effect of MVI, EHS, and ECOG PS on outcome in patients with advanced HCC treated with sorafenib: Analysis of two phase III, randomized, double-blind trials [abstract 4580]. ASCO; 2009
   Google Scholar
• Cheng AL, Guan Z, Chen Z, Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia-Pacific trial. Eur J Cancer 2012; [Epub ahead of print]
   Google Scholar
• Marrero J, Lencioni R, Kudo M, Global investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafenib (GIDEON) second interim analysis in more than 1,500 patients: clinical findings in patients with liver dysfunction. J Clin Oncol 2011;29: [abstract 4001]
   Google Scholar
• Iavarone M, Cabibbo G, Piscaglia F, Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology 2011;54:2055-63
   PubMed Web of Science ®Google Scholar
• Vincenzi B, Santini D, Russo A, Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. Oncologist 2010;15:85-92
   PubMed Web of Science ®Google Scholar
• Bettinger D, Schultheiß M, Knuppel E, Diarrhea predicts a positive response to sorafenib in patients with advanced hepatocellular carcinoma. Hepatology 2012; doi: 10.1002/hep.25637.
   PubMedGoogle Scholar
• Richly H, Kupsch P, Passage K, Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer. Int J Clin Pharmacol Ther 2004;42:650-1
   PubMedGoogle Scholar
• Abou-Alfa GK, Johnson P, Knox JJ, Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA 2010;304:2154-60
   PubMed Web of Science ®Google Scholar
• Petrini I LM, Ricasoli M. A phase II (PhII) trial of sorafenib (S) in combination with 5fluorouracil (5FU) continuous infusion in patients with advanced hepatocellular carcinoma (HCC) [abstract 4592]. ASCO; 2009
   Google Scholar
• Shen Y, Hsu CH, Lin Z. A phase II study of sorafenib in combination with tegafur/uracil (UFUR) for Asian patients with advanced hepatocellular carcinoma (HCC) [abstract 4589]. ASCO; 2009
   Google Scholar
• Gomez-Martin C, Bustamante J, Castroagudin JF, Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation. Liver Transpl 2012;18:45-52
   PubMed Web of Science ®Google Scholar
• Feun LG, Levi D, Moon J. Sorafenib in hepatocellular carcinoma (HCC) patients after liver transplantation [abstract 5579]. ASCO; 2009
   Google Scholar
• Truesdale AE, Caldwell SH, Shah NL, Sorafenib therapy for hepatocellular carcinoma prior to liver transplant is associated with increased complications after transplant. Transpl Int 2011;24:991-8
   PubMedGoogle Scholar
• Edmonds K, Hull D, Spencer-Shaw A, Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: recommendations from a European nursing task group. Eur J Oncol Nurs 2012;16:172-84
   PubMed Web of Science ®Google Scholar
• Pinter M, Sieghart W, Hucke F, Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib. Aliment Pharmacol Ther 2011;34:949-59
   PubMed Web of Science ®Google Scholar
• Pinter M, Sieghart W, Graziadei I, Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. Oncologist 2009;14:70-6
   PubMed Web of Science ®Google Scholar